In Sequence Survey: Illumina Holds Two-Thirds of Sequencing Market, Splits Desktop Share with Ion PGM | GenomeWeb

Illumina currently holds around 66 percent of the total sequencing market, but the company's share of the desktop market is split evenly with Life Technologies' Ion Torrent PGM, according to a recent survey of 150 In Sequence readers.

The survey, conducted in collaboration with investment firm Mizuho Securities, found that Illumina's HiSeq 2000, GA IIx, and MiSeq claim a total of 66 percent of the sequencing market — 42 percent, 10 percent, and 11 percent, respectively.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.